Vosoritide clinical trials
Also written BMN 111.
How each study uses vosoritide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vosoritide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Nov 2021 · VOXZOGO · NDA 214938 (FDA, Drugs@FDA)
- European Union
- 26 Aug 2021 · Voxzogo · EMEA/H/C/005475 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 3
BioMarin Pharmaceutical (14) · Andrew Dauber (1) · University of California, San Francisco (1) · Roopa Kanakatti Shankar, MBBS, MS (1)
Studies
Open first, then newest update. How each study uses vosoritide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaEnrolling by invitationPhase 3BioMarin PharmaceuticalNCT07073014Written as Vosoritide
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short StatureRecruitingPhase 2BioMarin PharmaceuticalNCT06382155Written as Vosoritide Injection
- A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsRecruitingPhase 2BioMarin PharmaceuticalNCT07126262Written as Vosoritide
- Vosoritide for Short Stature in Turner SyndromeRecruitingPhase 2Roopa Kanakatti Shankar, MBBS, MSNCT05849389Written as Vosoritide
- A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentTerminatedPhase 2BioMarin PharmaceuticalNCT06668805Written as Vosoritide Injection
- Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaCompletedPhase 3BioMarin PharmaceuticalNCT06455059Written as Vosoritide
- Vosoritide for Selected Genetic Causes of Short StatureActive, not recruitingPhase 2Andrew DauberNCT04219007Written as Vosoritide
- A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With AchondroplasiaActive, not recruitingPhase 2BioMarin PharmaceuticalNCT04554940Written as vosoritide
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaActive, not recruitingPhase 3BioMarin PharmaceuticalNCT03424018Written as BMN 111
- An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaActive, not recruitingPhase 2BioMarin PharmaceuticalNCT03989947Written as Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
- A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)Active, not recruitingPhase 2BioMarin PharmaceuticalNCT02724228Written as BMN 111
- Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VIActive, not recruitingPhase 1/2University of California, San FranciscoNCT05845749Written as Vosoritide Injection [Voxzogo]
- A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With AchondroplasiaCompletedPhase 2BioMarin PharmaceuticalNCT03583697Written as BMN 111
- Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy ParticipantsTerminatedPhase 1BioMarin PharmaceuticalNCT05813314Written as BMN 111 administration via Injector Pen
- A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaCompletedPhase 3BioMarin PharmaceuticalNCT03197766Written as BMN 111
- A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With AchondroplasiaCompletedPhase 2BioMarin PharmaceuticalNCT02055157Written as BMN 111
- A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult VolunteersCompletedPhase 1BioMarin PharmaceuticalNCT01590446Written as BMN 111
As the comparator · 1 — what is tested is compared with vosoritide
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
- A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentTerminatedNov 13, 2026NCT06668805
Codes
What other systems call vosoritide · ClinicalTrials.gg INT001131
- MeSH (NLM) C000632572vosoritideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7SE5582Q2PVOSORITIDEConfirmed FDA, NLM
- RxNorm 2586354One source FDA
- NCI Thesaurus C152918VosoritideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632572 | vosoritide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7SE5582Q2P | VOSORITIDE | Confirmed FDA, NLM |
| RxNorm | 2586354 | — | One source FDA |
| NCI Thesaurus | C152918 | Vosoritide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.